Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Depreciation and Depletion (2016 - 2017)

Intellia Therapeutics (NTLA) has disclosed Depreciation and Depletion for 3 consecutive years, with $660000.0 as the latest value for Q1 2017.

  • Quarterly Depreciation and Depletion rose 252.94% to $660000.0 in Q1 2017 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Mar 2017, up 246.48% year-over-year, with the annual reading at $3.0 million for FY2017, 172.73% up from the prior year.
  • Depreciation and Depletion for Q1 2017 was $660000.0 at Intellia Therapeutics, up from $401000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $660000.0 in Q1 2017, with the low at $33000.0 in Q1 2015.
  • Average Depreciation and Depletion over 3 years is $228888.9, with a median of $187000.0 recorded in 2016.
  • Peak annual rise in Depreciation and Depletion hit 466.67% in 2016, while the deepest fall reached 176.04% in 2016.
  • Over 3 years, Depreciation and Depletion stood at $104000.0 in 2015, then soared by 285.58% to $401000.0 in 2016, then skyrocketed by 64.59% to $660000.0 in 2017.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $660000.0, $401000.0, and $265000.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.